Parabilis has achieved the first pharmacological proof-of-concept for degrading the long-considered ‘undruggable’ transcription factor ERG in prostate cancer. DDW’s Megan Thomas speaks with Dr Jonathan Hurov, Executive Vice President, Discovery Biology at Parabilis Medicines, about the milestone. MT: ERG has been considered ‘undruggable’ for decades. Why is this? JH: ERG… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With conference season in full swing and the speakers announced for DDW’s Turning Science into… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With conference season in full swing and the speakers announced for DDW’s Turning Science into… Read More
Halo Biosciences has announced publication of results in Thorax from the Phase IIa SATURN study for patients with pulmonary hypertension and interstitial lung disease (PH-ILD). The study, conducted at Stanford University, evaluated 4-methylumbelliferone (4-MU) in patients with pulmonary hypertension, a highly progressive disease with significant unmet needs. The Phase IIa… Read More
Researchers at University of California San Diego School of Medicine have developed a gene therapy for Alzheimer’s disease (AD) that could help protect the brain from damage and preserve cognitive function. Unlike existing treatments for AD that target unhealthy protein deposits in the brain, the new approach could help address… Read More
Here, we provide an overview of the c-level moves that have taken place within the industry between April and June 2025. The ABPI has confirmed that Russell Abberley is the latest President-elect. Abberley, Vice President and General Manager of Amgen UK and Ireland, formally took up the Presidency on 13… Read More
Biopharmaceutical company Absci has transitioned into a clinical-stage organisation with the dosing of patients in its Phase I clinical trial of ABS-101. ABS-101 is the company’s investigational anti-TL1A antibody targeting inflammatory bowel disease, engineered using Absci’s generative AI platform. “We are excited to advance ABS-101 into Phase I clinical trials,”… Read More
Biotechnology company Nuclera and life sciences organisation Cytiva have announced a collaboration focused on accelerating the production, purification and characterisation of proteins required for drug research and development. The companies aim to enable this goal through the combination of Nuclera’s eProtein Discovery System with Cytiva’s Biacore surface plasmon resonance (SPR) technology. Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Dr Emil Lou,… Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Dr Emil Lou,… Read More
Scientists have obtained new data on many of the proteins responsible for regulating the cell cycle – a sequence of molecular events that culminates in the production of two daughter cells. A dysregulated cell cycle is a hallmark of several diseases, including cancer. This information will not only provide the… Read More
BIAL, a biopharmaceutical company focused on neurosciences and rare diseases, will give an oral presentation on its potential disease-modifying compound, BIA 28-6156, at the GBA1 Meeting 2025 being held 5-7 June 2025, in Montreal, Canada. The GBA1 Meeting 2025 is hosted by McGill University, focusing on all aspects of GBA1… Read More
The UK National Institute for Health and Care Excellence (NICE) has published updated Final Draft Guidance recommending AstraZeneca’s Forxiga (dapagliflozin) as an option to treat chronic kidney disease (CKD) in adults in certain cases. This is the case if: It is an add-on to optimised standard care including the highest… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. News stories of note for this week include a major deal signed between Eli… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. News stories of note for this week include a major deal signed between Eli… Read More
Biotech Tessera Therapeutics has presented updates across its in vivo genetic medicine programmes for Alpha-1 antitrypsin deficiency (AATD), Phenylketonuria (PKU), and Sickle Cell Disease (SCD), as well as advances in in vivo T cell therapies. These data were shared across four oral presentations and three poster presentations at the American Society of Gene and… Read More
